Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged ≥65 Years

Drugs and Aging

Volumn 26, Issue 9, 2009, Pages 751-767

  Gradman, Alan H ^a  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BISOPROLOL; CANDESARTAN HEXETIL; CARVEDILOL; DOXAZOSIN; EPLERENONE; EPROSARTAN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; METOPROLOL; NITRENDIPINE; OLMESARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ACUTE HEART INFARCTION; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG FORMULATION; DRUG TOLERABILITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

AGED; AGED, 80 AND OVER; AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GERIATRICS; HUMANS; HYPERTENSION; MALE; TREATMENT OUTCOME;

EID: 69949125930     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11316790-000000000-00000     Document Type: Review

References (121)

1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008 May 3; 371 (9623): 1513-1518
2. Kaplan NM. Systemic hypertension: an overview of the problem. Semin Nephrol 2005 Jul; 25 (4): 191-193
3. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007 Jan; 49 (1): 69-75
4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903-1913
5. Kassai B, Boissel JP, Cucherat M, et al. Treatment of high blood pressure and gain in event-free life expectancy. Vasc Health Risk Manag 2005; 1 (2): 163-169
6. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of ran-domised trials. BMJ 2008 May 17; 336 (7653): 1121-1123
7. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002 Feb 27; 287 (8): 1003-1010 (Pubitemid 34252058)
8. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-1252 [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/ hypertension/ [Accessed 2009 Jun 18]
9. Weber MA. Outcomes of treating hypertension in the elderly: a short commentary on current issues. Am J Geriatr Cardiol 2003 Jan-Feb; 12 (1): 14-18
10. Gradman AH, Morsy M. Hypertension in the elderly. Cardiol Rev 2006; 23 (9): 24-38
11. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995 Mar; 25 (3): 305-313
12. Franklin SS, Gustin 4th W, Wong ND, et al. Hemo-dynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997 Jul 1; 96 (1): 308-315
13. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001 Mar; 37 (3): 869-874
14. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999 Jul 27; 100 (4): 354-360
15. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001 Mar 6; 103 (9): 1245-1249
16. Mancia G, Parati G. The role of ambulatory blood pressure monitoring in elderly hypertensive patients. Blood Press Suppl 2000; 2: 12-16 (Pubitemid 30750056)
17. Chavanu K, Merkel J, Quan AM. Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 2008 Feb 1; 65 (3): 209-218
18. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihyper-tensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005 Dec 10; 366 (9502): 2026-2033
19. Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004 Mar; 35 (3): 776-785
20. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527-1535
21. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007 May; 25 (5): 951-958
22. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005 Aug; 46 (2): 386-392
23. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008 May 1; 358 (18): 1887-1898
24. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991 Jun 26; 265 (24): 3255-3264
25. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997 Sep 13; 350 (9080): 757-764
26. Kostis JB, Davis BR, Cutler J, et al., SHEP Cooperative Research Group. Prevention of heart failure by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997 Jul 16; 278 (3): 212-216
27. Perry Jr HM, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000 Jul 26; 284 (4): 465-471
28. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006 Mar; 47 (3): 345-351
29. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of is-chemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007 May 29; 115 (21): 2761-2788
30. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008 Dec; 31 (12): 2115-2127
31. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002 Nov-Dec; 4 (6): 393-404
32. Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: achieve blood pressure goals. J Clin Hypertens (Greenwich) 1999 Oct; 1 (2): 141-147
33. Gradman AH. Drug combinations. In: Izzo JL, Black HR, Sica DA, editors. Hypertension primer. 4th ed. Philadelphia (PA): Lippincott, Williams and Wilkins, 2008
34. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-2997
35. Meredith PA, Murray LS, McMurray JJ. A putative placebo comparison of the SCOPE and LIFE trials. J Renin Angiotensin Aldosterone Syst 2004 Jun; 5 (2): 59-63
36. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006 Nov; 24 (11): 2163-2168
37. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000 Apr 19; 283 (15): 1967-1975
38. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998 Jun 17; 279 (23): 1903-1907
39. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003 (Pubitemid 34286536)
40. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre rando-mised controlled trial. Lancet 2005 Sep 10-16; 366 (9489): 895-906
41. National Collaborating Centre for Chronic Conditions. Hypertension: management in adults in primary care: pharmacological update. London: Royal College of Physicians, 2006
42. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 Nov 13; 349 (20): 1893-1906
43. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with ni-trendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005 Jun; 36 (6): 1218-1226
44. Trenkwalder P, Elmfeldt D, Hofman A, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE)-major CV events and stroke in subgroups of patients. Blood Press 2005; 14 (1): 31-37
45. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001 Dec 11; 104 (24): 2996-3007
46. Tepper D. Frontiers in congestive heart failure: effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail 1999 Jul; 5 (4): 184-185
47. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 May 31; 344 (22): 1651-1658 (Pubitemid 32479962)
48. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994 Oct; 90 (4): 1765-1773
49. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 Aug 1; 325 (5): 293-302
50. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993 Oct 2; 342 (8875): 821-828
51. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandola-pril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995 Dec 21; 333 (25): 1670-1676
52. Cohn JN, Tognoni G. A randomized trial of the angio-tensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 Dec 6; 345 (23): 1667-1675
53. Pitt B, Zannad F, Remme WJ, et al. The effect of spir-onolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep 2; 341 (10): 709-717
54. McMurray J, Ostergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur J Heart Fail 2003 Jun; 5 (3): 261-270
55. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003 Jan 1; 41 (1): 159-168 (Pubitemid 36044419)
56. b-Blocker Heart Attack Trial Research Group (B-HAT). A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982 Mar 26; 247 (12): 1707-1714
57. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of cap-topril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992 Sep 3; 327 (10): 669-677
58. Dargie HJ. Effect of carvedilol on outcome after myo-cardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001 May 5; 357 (9266): 1385-1390
59. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 Apr 3; 348 (14): 1309-1321
60. Anderson RE, Pfeffer MA, Thune JJ, et al. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Am Heart J 2008 Apr; 155 (4): 706-711
61. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3): 145-153
62. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003 Feb 13; 348 (7): 583-592
63. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003 Apr 23-30; 289 (16): 2073-2082
64. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 Sep 6; 362 (9386): 782-788
65. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 Dec 3; 290 (21): 2805-2816
66. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003 Jan; 26 Suppl. 1: S80-2
67. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 Feb; 39 (2 Suppl. 1): S1-266
68. UK Prospective Diabetes Study Group. Efficacy of ateno-lol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998 Sep 12; 317 (7160): 713-720
69. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993 Nov 11; 329 (20): 1456-1462
70. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861-9 71.
71. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 851-860.
72. The GISEN Group (Gruppo Italiano di Studi Epidemio-logici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997 Jun 28; 349 (9069): 1857-1863
73. Wright Jr JT, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002 Jul 22; 162 (14): 1636-1643
74. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep 29; 358 (9287): 1033-1041
75. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypo-tension, pure autonomic failure, and multiple system atrophy. Neurology 1996 May; 46 (5): 1470
76. Applegate WB, Davis BR, Black HR, et al. Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. J Am Geriatr Soc 1991 Nov; 39 (11): 1057-1064
77. Luukinen H, Koski K, Laippala P, et al. Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch Intern Med 1999 Feb 8; 159 (3): 273-280
78. Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998 Nov 24; 98 (21): 2290-2295
79. Hajjar I. Postural blood pressure changes and orthostatic hypotension in the elderly patient: impact of anti-hypertensive medications. Drugs Aging 2005; 22 (1): 55-68 80.
80. Cooper R, Rotimi C. Hypertension in blacks. Am J Hyper-tens 1997 Jul; 10 (7 Pt 1): 804-812
81. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000 Apr; 13 (4 Pt 1): 418-426
82. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers: differences in potency and efficacy. Blood Press 2002; 11 (5): 293-301
83. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001 Sep-Oct; 3 (5): 283-91, 318
84. Xi GL, Cheng JW, Lu GC. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens 2008 May; 21 (5): 546-552
85. Neutel JM. Clinical studies of CS-866, the newest angio-tensin II receptor antagonist. Am J Cardiol 2001 Apr 19; 87 (8A): 37C-43C
86. Written communication: integrated summary of effectiveness report CS-866. Parsippany (NJ): Daiichi Sankyo, Inc., 2009. (Data on file
87. Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther 2000 Oct; 22 (10): 1213-1224
88. Morgan T, Anderson A, Bertram D, et al. Effect of can-desartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 2004 Jun; 5 (2): 64-71
89. Palatini P, Mugellini A, Spagnuolo V, et al. Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-Syst Study). Blood Press Monit 2004 Apr; 9 (2): 91-97
90. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999 Nov; 12 (11 Pt 1): 1130-1134
91. Neldam S, Forsen B. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydro-chlorothiazide. Drugs Aging 2001; 18 (3): 225-232
92. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25 (6): 1105-1187 (Pubitemid 46924065)
93. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007 Aug; 120 (8): 713-719
94. Kjeldsen SE, Os I, Hoieggen A, et al. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydro-chlorothiazide. Am J Cardiovasc Drugs 2005; 5 (1): 17-22
95. Izzo Jr JL, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens 2007 Jan; 9 (1): 36-44
96. Chrysant SG, Melino M, Lee J, et al. Long-term efficacy of amlodipine besylate + olmesartan medoxomil combination in achieving blood pressure goals in subjects > = 65 years of age [abstract]. J Clin Hypertens 2008; 10 Suppl. A (5): A14
97. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and val-sartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hy-pertens (Greenwich) 2007 May; 9 (5): 355-364
98. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30 (4): 587-604
99. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007 Apr; 29 (4): 563-580
100. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007 Mar; 21 (3): 220-224
101. Pedrinelli R, blockers, postural vasoconstriction and dependent oede-ma in essential hypertension. J Hum Hypertens 2001 Jul; 15 (7): 455-461
102. Oparil S, Ramstad D, Melino M, et al. The combination of amlodipine besylate + olmesartan medoxomil provides numerically greater reductions in blood pressure compared with component monotherapies in race and ethnic subgroups [abstract]. J Clin Hypertens 2008; 10 Suppl. A (5): A30
103. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007; 3 (6): 999-1005
104. Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich) 2007 Sep; 9 (9): 692-700
105. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003 May; 21 (5): 875-886 (Pubitemid 36677151)
106. Teveten (eprosartan mesylate) 400 mg and 600 mg [prescribing information]. North Chicago (IL): Abbott Laboratories, 2007
107. Atacand (candesartan cilexetil) tablets [prescribing information]. Wilmington (DE): AstraZeneca, 2007
108. Micardis (telmisartan) tablets, 20 mg, 40 mg and 80 mg [prescribing information]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 2006
109. Benicar tablets (olmesartan medoxomil) [prescribing information]. Parsippany (NJ): Daiichi Sankyo, Inc., 2006
110. Cozaar (losartan potassium tablets) [prescribing information]. Whitehouse Station (NJ): Merck & Co. Inc., 2003
111. Diovan (valsartan) tablets [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2007
112. Avapro (irbesartan) tablets [prescribing information]. New York: Bristol-Myers Squibb Sanofi Synthelabo Partnership, 2007
113. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004 Jun 19; 363 (9426): 2049-2051
114. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000 May 6; 355 (9215): 1582-1587
115. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 G, Mariani M. Calcium channel with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997 Mar 15; 349 (9054): 747-752
116. Konstam MA, Neaton JD, Poole-Wilson PA, et al. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J 2005 Jul; 150 (1): 123-131
117. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL rando-mised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002 Sep 7; 360 (9335): 752-760
118. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547-1559
119. Gradman AH, Alfayoumi F. From left ventricular hyper-trophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006 Mar-Apr; 48 (5): 326-341
120. Kjeldsen SE, Lyle PA, Kizer JR, et al. The effects of lo-sartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hyper-trophy. The LIFE study. J Clin Hypertens (Greenwich) 2005 Mar; 7 (3): 152-158
121. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363 (9426): 2022-2031